{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:44:41Z","timestamp":1761101081288,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1043,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Genzyme Corp"},{"name":"Genzyme Corporation"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.bbmt.2011.10.041","type":"journal-article","created":{"date-parts":[[2011,11,10]],"date-time":"2011-11-10T02:59:19Z","timestamp":1320893959000},"page":"913-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"18","author":[{"given":"Koen","family":"van Besien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Rich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter H.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"del Cerro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Artz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.10.041_bib1","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","author":"Luger","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared with myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib4","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","article-title":"Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"van Besien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.10.041_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/10428194.2010.538777","article-title":"T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed lymphoma. Predictors for survival after transplant relapse","volume":"52","author":"Kenkre","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.10.041_bib6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.transci.2004.10.008","article-title":"Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin\u2019s lymphoma (NHL)","volume":"32","author":"Morris","year":"2005","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2011.10.041_bib7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.10.041_bib8","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2011.10.041_bib9","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1182\/blood.V96.10.3537","article-title":"Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria","volume":"96","author":"Genini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib10","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib11","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1200\/JCO.2008.18.8706","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Jeha","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.10.041_bib12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2003-06-2122","article-title":"Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia","volume":"103","author":"Jeha","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib13","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1002\/cncr.25603","article-title":"Efficacy and safety of clofarabine in relapsed and\/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients","volume":"117","author":"Nabhan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2011.10.041_bib14","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/blood-2007-11-124602","article-title":"A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2007-03-081364","article-title":"A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias","volume":"110","author":"Karp","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib16","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/bmt.2010.32","article-title":"Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML","volume":"45","author":"Locke","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib17","unstructured":"ASBMT RFI Disease classifications. Retrieved September 27, 2011 from http:\/\/asbmt.org\/displaycommon.cfm?an=1&subarticlenbr=35."},{"key":"10.1016\/j.bbmt.2011.10.041_bib18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2011.10.041_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.bbmt.2011.10.041_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"10.1016\/j.bbmt.2011.10.041_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1705249","article-title":"Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning","volume":"37","author":"Kline","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib22","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3109\/10428190903200790","article-title":"Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence","volume":"50","author":"van Besien","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.10.041_bib23","unstructured":"Common terminology criteria for adverse events (CTCAE) and\u00a0common toxicity criteria (CTC). Retrieved on September 28, 2011 from http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"key":"10.1016\/j.bbmt.2011.10.041_bib24","first-page":"825","article-title":"Consensus conference on GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib26","unstructured":"CIBMTR data management manual. Retrieved on September 28, 2011 from http:\/\/www.cibmtr.org\/DataManagement\/TrainingReference\/Manuals\/DataManagement\/pages\/index.aspx."},{"key":"10.1016\/j.bbmt.2011.10.041_bib27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703260","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussions)","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0R Statist Soc B"},{"key":"10.1016\/j.bbmt.2011.10.041_bib29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1053\/j.ajkd.2010.07.002","article-title":"Estimation of GFR: a comparison of new and established equations","volume":"56","author":"Cirillo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bbmt.2011.10.041_bib31","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2003.04.031","article-title":"Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers","volume":"21","author":"Kantarjian","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.10.041_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/leu.2010.319","article-title":"Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia","volume":"25","author":"Farag","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.10.041_bib33","doi-asserted-by":"crossref","first-page":"a35","DOI":"10.1182\/blood.V116.21.35.35","article-title":"Allogeneic hematopoietic stem cell transplantation with clofarabine\/busulfan \u00d7 4 conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML","volume":"116","author":"Mineishi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib35","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/j.bbmt.2010.12.101","article-title":"Preliminary results of phase I\/II study of clofarabine incombination with cytarabine and total body irradiation followed by allogeneic stem cell transplantation in children, adolescents and young adults with poor-risk acute leukemia","volume":"17","author":"Ricci","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib36","first-page":"S224","article-title":"Clofarabine versus fludarabine for haploidentical stem cell transplantation in paediatric patients with refractory leukaemias","volume":"43","author":"Teltschik","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib37","doi-asserted-by":"crossref","first-page":"S298","DOI":"10.1016\/j.bbmt.2010.12.435","article-title":"Preliminary results of a phase II trial of clofarabine with parenteral busulfan followed by allogeneic transplantation for the treatment of hematologic malignancies","volume":"17","author":"Agura","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib38","article-title":"A phase I study in adults of clofarabine combined with high-dose melphalan as reduced intensity conditioning for allogeneic transplantation","author":"Kirschbaum","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib40","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","article-title":"Chronic graft-versus-host disease: long-term results from a randomized trial on GvHD prophylaxis with or without anti-T-cell globulin ATG-fresenius","volume":"117","author":"Socie","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib41","first-page":"2154","article-title":"Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"51","author":"O\u2019Donnell","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.10.041_bib42","article-title":"Allogeneic stem cell transplantation in renal failure. engraftment and prolonged survival, but high incidence of neurologic toxicity","author":"van Besien","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2011.10.041_bib43","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","article-title":"Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older","volume":"108","author":"Faderl","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib44","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","article-title":"Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia","volume":"24","author":"Jeha","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.10.041_bib45","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/sj.bmt.1704763","article-title":"Cardiac toxicity of high-dose chemotherapy","volume":"35","author":"Morandi","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib46","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1704166","article-title":"Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies","volume":"32","author":"van Besien","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib47","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2003-07-2345","article-title":"Cardiac toxicity of alemtuzumab in patients with mycosis fungoides\/Sezary syndrome","volume":"104","author":"Lenihan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.041_bib48","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2010.04.003","article-title":"Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation","volume":"17","author":"Beitinjaneh","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.041_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/bmt.2008.423","article-title":"Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG","volume":"44","author":"Martin","year":"2009","journal-title":"Bone Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:40:57Z","timestamp":1761057657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111004666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1083879111004666"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.041","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}